



LAO PEOPLE 'S DEMOCRATIC REPUBLIC
PEACE INDEPENDENCE DEMOCRACY UNITY PROSPERITY

MINISTRY OF HEALTH
FOOD AND DRUG DEPARTMENT
TEL (856 21) 214013, 214014
FAX: (856 21) 214015.

Certificate of Drug Registration

Registration Number:

10 L 1222/24

ALIDABRAFENIB

Dosage Form:	CAPSULE
Active Ingredient/s:	DABRAFENIB MESYLATE 75 MG
Description:	RED CAPSULE CONTAINS WHITE POWDER.
Size of packaging unit:	BOTTLE, 120 CAPSULES/BOTTLE
Indications:	- USED TO TREAT UNRESECTABLE OR METASTATIC MELANOMA PATIENTS WITH BRAF V600E MUTATION POSITIVITY. - USED FOR POSTOPERATIVE ADJUVANT TREATMENT OF BRAF V600E MUTATION POSITIVE MELANOMA. - USED TO TREAT METASTATIC NON-SMALL CELL LUNG CANCER CAUSED BY BRAF V600E MUTATION

Manufactured by: LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY
Address: SAYSETHA DEVELOPMENT ZONE, NANO VILLAGE, SAYSETHA DISTRICT, VIENTIANE
CAPITAL, LAO PDR
Telephone: +856 21 737 051

Manufacturer's licence: 2506/220620

This Certificate is issued to attest that the product described above has met the minimum standards required for drug registration undertaken by the **Food and Drug Department in Lao PDR**.

This certificate expires, unless previously suspended or revoked, on **30 October 2029**.

Note: All boxes and packaging must bear the *Lao Registration No.* **10 L 1222/24**

Vientiane, 31 October 2024

Director General of FDD



Bounxou KEOHAVONG MSc, PhD